# Anti-inflammatory and Anti-thrombotic Therapy With colcHicine and Low Dose Rivaroxaban for Major Adverse Cardiovascular Events Reduction in Ischemic Stroke

Study · id `cardio:ct-nct06396858` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06396858](<https://clinicaltrials.gov/study/NCT06396858>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT06396858

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 4500 participants.

## Technical summary

Registry record NCT06396858. Randomized; quadruple masking; primary purpose prevention. Start 2027-01 (anticipated); primary completion 2028-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 4500 participants (planned count; ClinicalTrials.gov record NCT06396858, source copy `cardio:ctgov-nct06396858-2026-10-30`, retrieved 2026-10-31)
- Planned start: 2027-01 (anticipated) (ClinicalTrials.gov record NCT06396858, source copy `cardio:ctgov-nct06396858-2026-10-30`, retrieved 2026-10-31)
- Primary completion: 2028-01 (anticipated) (ClinicalTrials.gov record NCT06396858, source copy `cardio:ctgov-nct06396858-2026-10-30`, retrieved 2026-10-31)
- Completion: 2028-05 (anticipated) (ClinicalTrials.gov record NCT06396858, source copy `cardio:ctgov-nct06396858-2026-10-30`, retrieved 2026-10-31)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06396858-2026-10-30`, retrieved 2026-10-31)

## The registry's words

- Brief title: Anti-inflammatory and Anti-thrombotic Therapy With colcHicine and Low Dose Rivaroxaban for Major Adverse Cardiovascular Events Reduction in Ischemic Stroke
- Acronym: ARCHIMEDES
- Condition: Ischemic Stroke
- Intervention (Drug): Rivaroxaban 2.5 Mg Oral Tablet
- Intervention (Drug): Colchicine 0.5 MG
- Intervention (Drug): Placebo Rivaroxaban
- Intervention (Drug): Placebo Colchicine
- Lead sponsor: Brazilian Clinical Research Institute
- Lead sponsor class: OTHER
- Collaborator: Alliança Diagnostic
- Collaborator class: UNKNOWN

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)

## Provenance

Content hash: 0bc018769f195ac3842ff306d532f01f6bb786293e10fc157396a7b9ed4a02bb
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
